Elderberry (Sambucus nigra) Evidence Based Nutritional Interventions in Respiratory and Immune Disorders

Abstract Elderberry (Sambucus nigra) is rich in anthocyanins and polyphenols and has long been used for respiratory health. This review synthesizes mechanistic and clinical evidence on elderberry as a nutritional adjunct for upper respiratory tract infections (URTI), influenza, the common cold, COVID-19/Long COVID, allergic airway diseases, rhinosinusitis, and pharyngitis, and outlines rational combinations with co-nutrients. Methods:We narratively integrated randomized controlled trials, meta-analyses, and in-vitro/in-vivo studies evaluating antiviral, anti-inflammatory, antioxidant, and immunomodulatory actions. Clinical endpoints included illness duration, symptom severity, medication use, and surrogate markers of inflammation/oxidative stress. We also appraised complementary roles of quercetin, bromelain, elastin peptides, mulberry leaf polyphenols, vitamin C, vitamin D, and zinc. Results:Elderberry exhibits multi-target mechanisms: it interferes with viral glycoprotein-host receptor interactions and early replication; down-regulates inflammatory signaling (e.g., NF-κB) and cytokines (TNF-α, IL-6); scavenges reactive species and activates Nrf2-dependent defenses (GSH, SOD, CAT); and enhances mucosal immunity (sIgA) and innate cell activity (macrophages, NK cells). Across RCTs in influenza/URTI, elderberry consistently shortened illness by ~1-2 days and reduced symptom scores, with some trials reporting decreased rescue medication. Evidence for COVID-19 is indirect - supported by anti-coronavirus in-vitro data and polyphenol-based mechanistic plausibility - but lacks large, definitive clinical trials. For allergic rhinitis/asthma and rhinosinusitis/pharyngitis, data are mainly mechanistic or small-scale, suggesting potential benefits in nasal congestion, throat pain, cough, and mucosal recovery. Co-nutrients provide complementary coverage across viral entry/replication, inflammatory amplification, oxidative stress, mucus rheology, and epithelial barrier repair. Conclusions:Elderberry is a plausible, evidence-supported adjunct for respiratory infections, with the strongest clinical signal in influenza and URTI. Early-stage use and deployment in susceptible populations may yield clinically meaningful symptom relief and faster recovery. Combination protocols with quercetin, bromelain, elastin peptides, mulberry leaf, vitamin C/D, and zinc are mechanistically coherent and may broaden benefits. Rigorous, adequately powered trials are still needed for COVID-19 and allergic/ENT indications. Elderberry should complement - rather than replace - standard medical care.